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Background
Recurrent or metastatic SCCHN has few effective thera-
peutic options. In these patients, the EXTREME regimen
added Cetuximab–an EGFR-specific monoclonal anti-
body–to a regimen of Platinum/5-FU and improved
median overall survival (OS) by 2.7 months and progres-
sion-free survival (PFS) by 2.3 months [1]. Given the
natural killer (NK) cell-mediated antibody dependent cellu-
lar cytotoxicity (ADCC) of Cetuximab-mediated tumor
killing and the immunogenic antitumor effects of che-
motherapeutics like Platinum and 5-FU, synergy with
immunotherapy may be one option to further improve
outcomes.
VTX-2337 (Motolimod), a novel Toll-like receptor 8
(TLR8) agonist, stimulates myeloid dendritic cells (mDC),
monocytes, and NK cells. Preclinical data have demon-
strated increased ADCC with IgG1 monoclonal antibodies
when Motolimod is added [2] as well as synergistic effects
when Motolimod is combined with chemotherapy [3]. A
Phase Ib study of Cetuximab and Motolimod in patients
with Platinum-refractory or -intolerant recurrent or meta-
static SCCHN has shown the combination to be both tol-
erable and active in this setting [4]. Translational medicine
correlates demonstrated TLR8 activation and enhanced
NK cell mobilization and activation. There is strong ratio-
nale to further assess the safety, tolerability, and efficacy of
this combination in SCCHN patients. A large trial in this
population will allow exploration of a number of transla-
tional medicine correlates to illuminate the combination
of immunotherapy with other anti-cancer therapies.
Methods
This randomized, double-blind, placebo-controlled, Phase
II study evaluates the safety and efficacy of Motolimod
with EXTREME vs. EXTREME alone for first-line treat-
ment of recurrent or metastatic SCCHN. Patients must
have a confirmed diagnosis, measurable disease, and no
prior systemic therapy for their recurrent or metastatic
disease. Approximately 175 patients will be randomized
1:1 to receive Motolimod or placebo + EXTREME for
6 cycles (q3wk), followed by weekly Cetuximab with
biweekly Motolimod/placebo. The primary objective is to
compare PFS according to immune-related response eva-
luation criteria between the two treatment arms, as deter-
mined by independent review. Secondary objectives
include comparisons of safety and OS between the two
treatment groups.
Translational studies will be conducted to compare
immune biomarker response by a multiplexed panel of
cytokines, chemokines, and inflammatory markers; genetic
polymorphisms that may impact response to a TLR8
agonist or to Cetuximab; and the effect of immune cell
subsets within the tumor on response to treatment and/or
clinical outcome between the two treatment groups.
Pharmacokinetics of Motolimod will also be evaluated.
Enrollment began in October 2013. (NCT01836029).3VentiRx Pharmaceuticals, Seattle, WA, USA
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